Athiwat Hutchaleelaha, Mira Patel, Carla Washington, Vincent Siu, Elizabeth Allen, Donna Oksenberg, Daniel D Gretler, Timothy Mant, Josh Lehrer-Graiwer
AIMS: Voxelotor (previously GBT440) is a hemoglobin (Hb) modulator that increases Hb-oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once-daily oral drug to treat sickle cell disease (SCD). This first-in-human study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of voxelotor in healthy volunteers and SCD patients. METHODS: A total of 40 healthy volunteers (100, 400, 1000, 2000, or 2800 mg) and 8 SCD patients (1000 mg) were randomly assigned to a single dose of voxelotor once daily (n = 6 per group) or placebo (n = 2 per group)...
February 11, 2019: British Journal of Clinical Pharmacology